Valore202020212022202320242025TTMSpese di vendita, generali e amministrative3.79 B4.36 B4.52 B5.19 B5.98 B6.89 B7.07 BRicerca e sviluppo1.14 B1.2 B1.32 B1.41 B1.61 B2.05 B2.13 BReddito operativo-80 M1.2 B1.65 B2.34 B2.6 B3.61 B3.79 BProventi non operativi, Totale1 M-123 M-508 M-358 M-407 M-96 M267 MOneri finanziari, al netto degli interessi capitalizzati361 M341 M470 M265 M305 M349 M357 MProventi non operativi, esclusi gli oneri finanziari-722 M-682 M-940 M-530 M-391 M-217 M-39 MEntrate/uscite straordinarie362 M218 M-38 M-93 M-321 M-228 M-51 MUtile al lordo delle imposte-79 M1.08 B1.14 B1.99 B2.28 B3.38 B3.74 BQuota di utile———————Imposte2 M36 M443 M393 M436 M493 M184 MInteressi di minoranza———1 M-8 M-6 M-6 MAltri proventi/oneri al netto delle imposte———————Utile netto al lordo delle attività cessate-82 M1.04 B698 M1.59 B1.85 B2.89 B3.56 BAttività cessate———————Utile netto-82 M1.04 B698 M1.59 B1.85 B2.89 B3.56 BRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari-115 M985 M642 M1.57 B1.85 B2.9 B3.56 BUtile base per azione (EPS base)-0.080.690.451.081.261.962.4Utile diluito per azione (EPS diluito)-0.080.690.451.071.251.942.39Numero medio di azioni ordinarie in circolazione1.42 B1.42 B1.43 B1.45 B1.47 B1.48 B—Azioni diluite in circolazione1.42 B1.43 B1.44 B1.46 B1.49 B1.49 B—EBITDA1.04 B2.29 B2.78 B3.54 B3.87 B4.98 B5.18 BEBIT-80 M1.2 B1.65 B2.34 B2.6 B3.61 B3.79 BCosto del fatturato3.46 B3.71 B3.96 B4.34 B5.26 B6.22 B6.36 BAltri costi del venduto149 M——————Ammortamento e svalutazione (liquidità)1.12 B1.09 B1.14 B1.2 B1.27 B1.37 B1.39 B
Boston Scientific Corporation Common Stock
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.